Consequently, it is plausible that tau PET might add important information beyond CSF biomarkers, for example, for defining AD subtypes (212) and predicting subsequent cognitive decline (185), but additional studies are needed and the implications for patient care remain unclear. This evidence concerns the gene MAPT and Alzheimer disease.